Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.56 |
| ▸ | CA1 | P00915 | 12/20 | 0.56 |
| ▸ | CA9 | Q16790 | 6/20 | 0.56 |
| ▸ | CA5A | P35218 | 4/20 | 0.56 |
| ▸ | CA7 | P43166 | 4/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA6 | P23280 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.56 |
| ▸ | CA3 | P07451 | 2/20 | 0.56 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.56 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PYGL | P06737 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1185864 | 0.85 | LMNA (0.69) | CA2CA1CA9CA5ACA7 | |
| SCHEMBL2807663 | 0.85 | TSHR (0.59) | CA2CA1CA9CA5ACA7 | |
| SCHEMBL27878677 | 0.84 | LMNA (0.67) | CA2CA1CA9CA5ACA7 | |
| SCHEMBL9516048 | 0.83 | TSHR (0.57) | CA2CA1CA9CA5ACA7 | |
| SCHEMBL7527853 | 0.83 | ALDH1A1 (0.58) | CA2CA1CA9CA5ACA7 | |
| SCHEMBL7824801 | 0.82 | CA2 (0.55) | CA2CA1CA9CA5ACA7 | |
| SCHEMBL18577911 | 0.81 | TSHR (0.55) | CA2CA1CA9CA5ACA7 | |
| SCHEMBL403618 | 0.81 | LMNA (0.74) | TSHRCASP1SMN1; SMN2LMNACYP2C19 | |
| SCHEMBL27530309 | 0.81 | ALDH1A1 (0.57) | CA2CA1CA9CA5ACA7 | |
| Hydrochloric Acid SCHEMBL9651756 | 0.80 | LMNA (0.72) | TSHRCASP1SMN1; SMN2LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12467928-B2 | N-terminal modifier agents and binders for treating and analyzing peptides | DF PEPTIDE ACQUISITION LLC | 2025-11-11 | — | — | US | disclosed |
| US-20240377408-A1 | N-TERMINAL MODIFIER AGENTS AND BINDERS FOR TREATING AND ANALYZING PEPTIDES | DF PEPTIDE ACQUISITION LLC | 2024-11-14 | — | — | US | disclosed |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20220283175-A1 | METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES | Encodia, Inc. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220283175-A1 | METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES | Encodia, Inc. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200190030-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-10647719-B2 | Bicyclic compounds as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180258043-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| US-20050288267-A1 | Estradiol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-29 | — | — | US | disclosed |
| US-20050282793-A1 | Steroid prodrugs with androgenic action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-22 | — | — | US | disclosed |
| US-20050277625-A1 | Estriol and estetrol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-15 | — | — | US | disclosed |
| WO-2005113574-A1 | AMINOSULPHONYL- OR AMINOSULPHONYLAMINO-SUBSTITUTED PHENYL ESTERS AS ESTRADIOL PRODRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005113575-A1 | STEROID PRODRUGS WITH ANDROGENIC EFFECT | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005113576-A1 | AMINOSULPHONYL- OR AMINOSULPHONYLAMINO-SUBSTITUTED PHENYL ESTERS AS ESTRIOL AND ESTETROL PRODRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-01 | — | — | WO | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1569647-A2 | CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS | SmithKline Beecham Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054581-A2 | CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190030-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CA2 3856/4885CA1 4396/4885CA9 3829/4885 |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CA2 3856/4885CA1 4396/4885CA9 3829/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CA2 3954/4885CA1 4482/4885CA9 3896/4885 |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CA2 3856/4885CA1 4396/4885CA9 3829/4885 |
| US-20050288267-A1 | Estradiol prodrugs | CYP19A1, ESR1, HSD17B11 | CA2 2551/4885CA1 2303/4885CA9 1880/4885 |
| US-20050282793-A1 | Steroid prodrugs with androgenic action | CYP21A2, CYP17A1, NR5A1 | CA2 2329/4885CA1 1614/4885CA9 575/4885 |
| US-20050277625-A1 | Estriol and estetrol prodrugs | HSD17B11, CYP19A1, ESR1 | CA2 3004/4885CA1 1643/4885CA9 2241/4885 |
| US-20180258043-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CA2 3856/4885CA1 4396/4885CA9 3829/4885 |
| US-10647719-B2 | Bicyclic compounds as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | CA2 238/4885CA1 1155/4885CA9 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.